|Bid||16.40 x 800|
|Ask||31.50 x 1000|
|Day's Range||20.25 - 22.70|
|52 Week Range||13.04 - 32.88|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.67|
-Single-doses were well-tolerated and showed reduction in pruritus-. -Data support plans for advancement into multiple chronic pruritic diseases, including prurigo nodularis-. HAMILTON, BERMUDA, Sept. ...
HAMILTON, Bermuda, Aug. 29, 2018-- Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for ...
HAMILTON, BERMUDA, Aug. 28, 2018-- Kiniksa Pharmaceuticals, Ltd. announced today that it will be presenting at the 2018 Wells Fargo Healthcare Conference on Thursday, September 6 th, 2018 at 8:00 a.m. ...
–Rilonacept advancing toward pivotal Phase 3 clinical trial in 2 H 2018 following recent End-of-Phase 2 communication with FDA–. –KPL-716 single-dose Phase 1 a/1b Last Subject Last Visit achieved; clinical ...
HAMILTON, Bermuda, Aug. 02, 2018-- Kiniksa Pharmaceuticals, Ltd. announced today that it will be presenting at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14 th, 2018 at 9:45 a.m. ...
In this analysis, my focus will be on developing a perspective on Kiniksa Pharmaceuticals Ltd’s (NASDAQ:KNSA) latest ownership structure, a less discussed, but important factor. A company’s ownership structure isRead More...